Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2012 2
2013 2
2016 1
2018 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Heberprot-P's Effect on Gene Expression in Healing Diabetic Foot Ulcers.
Camacho-Rodríguez H, Guillen-Pérez IA, Roca-Campaña J, Baldomero-Hernández JE, Tuero-Iglesias ÁD, Galván-Cabrera JA, Rodriguez-Cordero M, Palenzuela-Gardón DO, Berlanga-Acosta J, Novoa-Pérez LI. Camacho-Rodríguez H, et al. Among authors: tuero iglesias ad. MEDICC Rev. 2018 Jul;20(3):10-14. doi: 10.37757/MR2018.V20.N3.4. MEDICC Rev. 2018. PMID: 31242156 Free article.
Pharmacokinetic and pharmacodynamic characterization of a novel formulation containing co-formulated interferons alpha-2b and gamma in healthy male volunteers.
García-García I, Hernández-González I, Díaz-Machado A, González-Delgado CA, Pérez-Rodríguez S, García-Vega Y, Campos-Mojena R, Tuero-Iglesias ÁD, Valenzuela-Silva CM, Cruz-Ramírez A, Martín-Trujillo A, Santana-Milián H, López-Saura PA, Bello-Rivero I; CIGB-128-A Study Group. García-García I, et al. Among authors: tuero iglesias ad. BMC Pharmacol Toxicol. 2016 Dec 7;17(1):58. doi: 10.1186/s40360-016-0103-8. BMC Pharmacol Toxicol. 2016. PMID: 27923408 Free PMC article. Clinical Trial.
Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers.
Yera-Alos IB, Alonso-Carbonell L, Valenzuela-Silva CM, Tuero-Iglesias AD, Moreira-Martínez M, Marrero-Rodríguez I, López-Mola E, López-Saura PA. Yera-Alos IB, et al. Among authors: tuero iglesias ad. BMC Pharmacol Toxicol. 2013 Sep 3;14:44. doi: 10.1186/2050-6511-14-44. BMC Pharmacol Toxicol. 2013. PMID: 24004460 Free PMC article.
Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.
García-Vega Y, García-García I, Collazo-Caballero SE, Santely-Pravia EE, Cruz-Ramírez A, Tuero-Iglesias AD, Alfonso-Alvarado C, Cabrera-Placeres M, Castro-Basart N, Duncan-Roberts Y, Carballo-Treto TI, Soto-Matos J, Izquierdo-Toledo Y, Vázquez-Blomquist D, García-Iglesias E, Bello-Rivero I. García-Vega Y, et al. Among authors: tuero iglesias ad. BMC Pharmacol Toxicol. 2012 Dec 28;13:20. doi: 10.1186/2050-6511-13-20. BMC Pharmacol Toxicol. 2012. PMID: 23272809 Free PMC article. Clinical Trial.
Granulation response and partial wound closure predict healing in clinical trials on advanced diabetes foot ulcers treated with recombinant human epidermal growth factor.
Valenzuela-Silva CM, Tuero-Iglesias ÁD, García-Iglesias E, González-Díaz O, Del Río-Martín A, Yera Alos IB, Fernández-Montequín JI, López-Saura PA. Valenzuela-Silva CM, et al. Among authors: tuero iglesias ad. Diabetes Care. 2013 Feb;36(2):210-5. doi: 10.2337/dc12-1323. Epub 2012 Sep 10. Diabetes Care. 2013. PMID: 22966096 Free PMC article. Clinical Trial.